Showing results (701-710 of 712) with videos related to

Sort By:
Pageof 72
Endocrine-Related Cancer|March 8, 2017
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposalS L Asa, O Casar-Borota, P Chanson, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkersJarushka Naidoo, Karisa C Schreck, Wei Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2025
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent GlioblastomaEudocia Q Lee, Brian M Alexander, Carlos G Romo, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Nature Medicine|July 10, 2026
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trialMichael Lim, Xiaobu Ye, Anna F Piotrowski, et al.
Journal of Clinical Medicine|July 29, 2023
The Association between Emergency Department Length of Stay and In-Hospital Mortality in Older Patients Using Machine Learning: An Observational Cohort StudyLijuan Wu, Xuanhui Chen, Anna Khalemsky, et al.
NPJ Digital Medicine|March 15, 2026
Artificial Intelligence-powered tiered early warning framework addressing high false alarm rates for in-hospital mortality predictionLijuan Wu, Liyi Mai, Hongnian Wang, et al.
Neuro-Oncology|August 12, 2021
Multimodal platform for assessing drug distribution and response in clinical trialsBegoña G C Lopez, Ishwar N Kohale, Ziming Du, et al.
Journal of Clinical Medicine|January 8, 2023
Length-of-Stay in the Emergency Department and In-Hospital Mortality: A Systematic Review and Meta-AnalysisDominique Lauque, Anna Khalemsky, Zoubir Boudi, et al.
Medrxiv : the Preprint Server for Health Sciences|August 30, 2024
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaVeronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Pageof 72